IBRX News

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class Action - Contact Lieff Cabraser

Class Action Reminder from Pomerantz LLP for Shareholders of ImmunityBio, Inc. – IBRX

IBRX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Class Action Lawsuit Reminder from Pomerantz LLP for Investors of ImmunityBio, Inc. – IBRX

IBRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA ® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027